Dr. Reddy's unit buys rights to Valeant's skin cream Cloderm

04/3/2011 | MSN

Dr. Reddy's Laboratories subsidiary Promius Pharma agreed to purchase U.S. development and marketing rights to Cloderm, Valeant Pharmaceuticals International's topical drug for skin disorders. Valeant will receive an upfront fee as well as royalties.

View Full Article in:

MSN

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Program Coordinator/Lecturer for the Regulatory Science program
Johns Hopkins University
Washington, DC
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Executive Officer
UCare Minnesota
Minneapolis, MN